ES3029609T3 - Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists - Google Patents
Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists Download PDFInfo
- Publication number
- ES3029609T3 ES3029609T3 ES15817206T ES15817206T ES3029609T3 ES 3029609 T3 ES3029609 T3 ES 3029609T3 ES 15817206 T ES15817206 T ES 15817206T ES 15817206 T ES15817206 T ES 15817206T ES 3029609 T3 ES3029609 T3 ES 3029609T3
- Authority
- ES
- Spain
- Prior art keywords
- bhba
- mmol
- mixture
- treatment
- rar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422472 | 2014-12-17 | ||
| PCT/EP2015/080029 WO2016097004A1 (en) | 2014-12-17 | 2015-12-16 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3029609T3 true ES3029609T3 (en) | 2025-06-24 |
Family
ID=55027725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15817206T Active ES3029609T3 (en) | 2014-12-17 | 2015-12-16 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9994559B2 (enExample) |
| EP (1) | EP3233842B1 (enExample) |
| JP (1) | JP6596090B2 (enExample) |
| KR (1) | KR102526625B1 (enExample) |
| CN (1) | CN107207488B (enExample) |
| AU (1) | AU2015367531B2 (enExample) |
| BR (1) | BR112017012588B8 (enExample) |
| CA (1) | CA2970574C (enExample) |
| ES (1) | ES3029609T3 (enExample) |
| IL (1) | IL252882B (enExample) |
| WO (1) | WO2016097004A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017012588B8 (pt) | 2014-12-17 | 2024-02-15 | King S College London | Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico |
| GB201610867D0 (en) * | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| CN111892591A (zh) * | 2019-05-06 | 2020-11-06 | 南京科技职业学院 | 一种维奈托克关键中间体的合成方法 |
| GB201907647D0 (en) * | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| US12486221B2 (en) | 2020-05-29 | 2025-12-02 | Basf Se | Preparation of substituted 4-(N′-hydroxycarbamimidoyl)benzoic acids |
| CN112552252B (zh) * | 2020-09-30 | 2024-01-02 | 浙江美诺华药物化学有限公司 | 一种氟雷拉纳中间体的制备方法 |
| CN113264832A (zh) * | 2021-05-13 | 2021-08-17 | 南京爱可德夫科技开发有限公司 | 一种合成高纯度2-氟-4-溴苯甲酸叔丁酯的方法 |
| CN116640071B (zh) * | 2023-05-04 | 2024-08-30 | 四川青木制药有限公司 | 一种制备2-甲基4-甲醛肟基苯甲酸及其酯类衍生物的方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996040634A1 (en) | 1995-06-07 | 1996-12-19 | Nippon Shinyaku Co., Ltd. | Pyrrole derivatives and medicinal composition |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| EP0889032A4 (en) * | 1996-03-18 | 2000-01-05 | Eisai Co Ltd | CARBOXYLIC ACID DERIVATIVES WITH FUSED CYCLES |
| JPH10158192A (ja) | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
| GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
| JP2000154150A (ja) * | 1997-10-22 | 2000-06-06 | Eisai Co Ltd | 腎炎予防・治療剤としてのレチノイン酸アゴニスト |
| WO1999020309A1 (en) | 1997-10-22 | 1999-04-29 | Eisai Co., Ltd. | Retinoic acid agonists as preventive and therapeutic agents for nephritis |
| EP1202990A2 (en) * | 1999-07-09 | 2002-05-08 | Ortho-McNeil Pharmaceutical, Inc. | Neurotrophic pyrrolidines and piperidines, and related compositions containing them |
| US20020048580A1 (en) * | 2000-06-07 | 2002-04-25 | Institut National De La Sante Et De La Recherche Medicale | Method of inducing lung branching |
| RU2003138074A (ru) | 2001-06-08 | 2005-02-20 | Цитови Инк. (US) | Замещенные 3-арил-5-арил-[1,2,4]-оксадиазолы и их аналоги в качестве активаторов каспаз и индукторов апоптоза, а также их применение |
| JP2003081832A (ja) | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| WO2003062230A1 (en) * | 2002-01-21 | 2003-07-31 | Eisai Co., Ltd. | Conbinatorial library of heterocycle compounds |
| KR20050033070A (ko) | 2002-08-09 | 2005-04-08 | 아스트라제네카 에이비이 | 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸 |
| EP3889142B1 (en) * | 2003-04-11 | 2022-06-15 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| KR20070067165A (ko) * | 2004-10-13 | 2007-06-27 | 피티씨 테라퓨틱스, 인크. | 넌센스 변이 억제용 화합물, 및 이의 사용 방법 |
| US20090176837A1 (en) | 2005-07-12 | 2009-07-09 | Sony Corporation | Compounds with activity at retinoic acid receptors |
| EP2304366A2 (en) | 2008-05-30 | 2011-04-06 | Foster Wheeler Energia Oy | Method of and system for generating power by oxyfuel combustion |
| KR101220182B1 (ko) * | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
| GB0915196D0 (en) * | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
| WO2011072281A1 (en) | 2009-12-11 | 2011-06-16 | Ptc Therapeutics, Inc. | Methods for treating methylmalonic acidemia |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| BR112017012588B8 (pt) * | 2014-12-17 | 2024-02-15 | King S College London | Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico |
-
2015
- 2015-12-16 BR BR112017012588A patent/BR112017012588B8/pt active IP Right Grant
- 2015-12-16 JP JP2017532660A patent/JP6596090B2/ja active Active
- 2015-12-16 CN CN201580073462.9A patent/CN107207488B/zh active Active
- 2015-12-16 US US15/533,492 patent/US9994559B2/en active Active
- 2015-12-16 WO PCT/EP2015/080029 patent/WO2016097004A1/en not_active Ceased
- 2015-12-16 EP EP15817206.4A patent/EP3233842B1/en active Active
- 2015-12-16 CA CA2970574A patent/CA2970574C/en active Active
- 2015-12-16 AU AU2015367531A patent/AU2015367531B2/en active Active
- 2015-12-16 KR KR1020177019558A patent/KR102526625B1/ko active Active
- 2015-12-16 ES ES15817206T patent/ES3029609T3/es active Active
-
2017
- 2017-06-13 IL IL252882A patent/IL252882B/en active IP Right Grant
-
2018
- 2018-06-05 US US15/997,796 patent/US10385044B2/en active Active
-
2019
- 2019-08-09 US US16/536,441 patent/US10752616B2/en active Active
-
2020
- 2020-08-19 US US16/997,855 patent/US11401265B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200131165A1 (en) | 2020-04-30 |
| US20190010146A1 (en) | 2019-01-10 |
| US20210130337A1 (en) | 2021-05-06 |
| US10385044B2 (en) | 2019-08-20 |
| EP3233842B1 (en) | 2025-03-26 |
| CA2970574A1 (en) | 2016-06-23 |
| IL252882A0 (en) | 2017-08-31 |
| KR102526625B1 (ko) | 2023-04-27 |
| EP3233842A1 (en) | 2017-10-25 |
| CN107207488B (zh) | 2020-11-17 |
| US20170327489A1 (en) | 2017-11-16 |
| KR20170097125A (ko) | 2017-08-25 |
| US10752616B2 (en) | 2020-08-25 |
| US11401265B2 (en) | 2022-08-02 |
| JP2017537967A (ja) | 2017-12-21 |
| AU2015367531A1 (en) | 2017-07-06 |
| JP6596090B2 (ja) | 2019-10-23 |
| BR112017012588B1 (pt) | 2023-11-07 |
| US9994559B2 (en) | 2018-06-12 |
| WO2016097004A1 (en) | 2016-06-23 |
| BR112017012588B8 (pt) | 2024-02-15 |
| EP3233842C0 (en) | 2025-03-26 |
| CN107207488A (zh) | 2017-09-26 |
| AU2015367531B2 (en) | 2020-04-30 |
| CA2970574C (en) | 2023-09-19 |
| IL252882B (en) | 2020-04-30 |
| BR112017012588A2 (pt) | 2018-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3029609T3 (en) | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists | |
| ES2550050T3 (es) | Compuestos de imidazo[4,5-b]piridin-2-ona y oxazolo[4,5-b]piridin-2-ona y análogos de los mismos como compuestos terapéuticos | |
| US10196358B2 (en) | KCNQ2-5 channel activator | |
| AU2013307688A1 (en) | Ddr2 inhibitors for the treatment of osteoarthritis | |
| ES2714100T3 (es) | Compuestos de quinolina fusionados como inhibidores de mTor, pi3k | |
| ES2297217T3 (es) | Derivados sustituidos de 2,4-dihidro-pirrolo(3,4-b)quinolin-9-ona utilizados como inhibidores de fosfodiesterasa. | |
| CN110709394B (zh) | 可用作alcat1抑制剂的化合物 | |
| ES2782357T3 (es) | Inhibidores de IRE 1 alfa | |
| US11584741B2 (en) | Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation | |
| CN118684661A (zh) | 杂芳基类化合物及其药物组合物、制备方法和用途 | |
| CN107880038A (zh) | [1,2,4]三唑并[1,5‑a]吡啶类化合物及其制备方法和医药用途 | |
| ES2609459T3 (es) | Compuestos heterocíclicos condensados y su uso | |
| ES2327416T3 (es) | Derivados de tetraidrocarbazol y su uso farmaceutico. | |
| CN103992311A (zh) | Hedgehog信号通路抑制剂 | |
| ES2630068T3 (es) | Derivado de la cumarina | |
| ES2367968T3 (es) | Sales de quino[4,3,2-kl]acridinio n8,n13-disustituidas utilizadas como agentes terapéuticos. | |
| ES2385103T3 (es) | Compuestos de imidazo[4,5-b]piridin-2-ona y análogos de los mismos como compuestos terapéuticos contra el cáncer | |
| BRPI0708098A2 (pt) | derivados de 4-benzoilaminofenil)-6,7-dimetóxi-2-metilaminoquinaz olina | |
| CN111763164A (zh) | 一类邻位羰基氨基取代苯衍生物的制备方法和用途 | |
| JP2023503470A (ja) | ガラクトセレブロシダーゼの活性の変質に関連する状態におけるアリールおよびヘテロアリール化合物、ならびにそれらの治療的使用 |